NCT04736823View on ClinicalTrials.gov

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

296

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2026

Conditions

NSCLC

Interventions

DRUG

AK112

IV infusion

DRUG

Pemetrexed

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Docetaxel

IV infusion

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-Sen University Cancer Center, Guanzhou

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY